Locus Coeruleus Volume is Reduced in Early Parkinson Disease-Related Orthostatic Hypotension.

Paul A. Beach  
Emory University School of Medicine  https://orcid.org/0000-0002-3657-7106

Nithin Kurra  
Emory University School of Medicine

Kristy Hwang  
Emory University School of Medicine

Jason Langley  
University of California Riverside

Xiaoping Hu  
University of California Riverside

Daniel E. Huddleston (✉ daniel.huddleston@emory.edu)  
Emory University School of Medicine  https://orcid.org/0000-0003-0503-3736

Research

Keywords: Locus coeruleus, Parkinson disease, Orthostatic hypotension, Neuromelanin MRI, Non-motor symptoms,

Posted Date: October 11th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-936643/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Orthostatic hypotension (OH) is common in Parkinson disease (PD) and often coincident with cognitive impairment. The locus coeruleus (LC), a central autonomic and cognitive regulator, may be a common pathophysiologic link. Here we tested whether LC structural pathology, measured by neuromelanin-sensitive MRI, is associated with OH, cognition, and OH symptom presence (OHSx) in PD.

Methods

PD motor exam, orthostatic vital signs (OVS), and depression, anxiety, and fatigue symptom scales were measured in 62 patients. Automated segmentation of LC and substantia nigra pars compacta (SNc, control region) took place using 3T MRI-based 2D T1-weighted and neuromelanin-sensitive sequences. LC/SNc volumes (mm$^3$) were compared between OH and no-OH patients (N=9 & 53) using MACOVA. One-tailed partial correlations (False discovery rate (FDR) corrected) between LC volume, OVS, and MoCA were measured. MANOVA tested for relationships between OHSx, LC/SNc volumes, OVS, and non-motor scales.

Results

LC, but not SNc, volumes were reduced in OH-patients, compared to no-OH (LC p=0.01; SNc p=0.44). LC volumes correlated with OVS (systolic blood pressure/SBP r=0.24, p$_{FDR}$=0.043; diastolic/DBP r=0.25, p$_{FDR}$=0.043; heart rate/HR r=-0.32, p$_{FDR}$=0.024) and with MoCA (r=0.22, p$_{FDR}$=0.043). OH-patients were more likely to endorse OHSx (Chi Sq. p=0.047). LC/SNc volumes were unrelated to OHSx but were associated with DBP change (F=4.3, p=0.043; SBP trended − F=3.8, p=0.055), and with greater depressive (F=6.6, p=0.012) and fatigue (F=5.13, p=0.027) symptoms.

Conclusions

This study supports LC as a neural substrate for OH and possibly cognitive decline in PD, but not OHSx, which were more associated with depressive and fatigue symptoms. A larger cohort of OH-patients is needed to validate these findings.

Introduction

Autonomic failure with orthostatic hypotension (OH) is common in Parkinson's disease (PD). While 50% of PD patients will develop OH at some point, upwards of at least 14% of early-stage patients develop OH (1–3). Despite only ~33% of patients with OH endorsing typical OH symptoms (OHSx) (4, 5), OH presence
confers increased morbidity and mortality, including risk of falls, impaired quality of life, and healthcare utilization (6, 7). Similarly, cognitive impairment, also a risk for quality of life reduction, is common in early PD (15-20% in de novo PD), with upwards of 80% of MCI-PD patients progressing to dementia (8–10). Interestingly, several studies have found those with OH, irrespective of OHSx, have a greater risk of cognitive impairment (11–14). Neuropathologic mechanisms underlying this link remain unclear.

Prevailing mechanistic understanding of PD-related OH relates to peripheral noradrenergic efferent alpha-synuclein neuropathology (15, 16), including denervation of sympathetic post-ganglionic myocardial and blood vessels nerves (17, 18). However, recent work has suggested a central contribution toward dysautonomia in PD, including OH (19–21). Such central substrates could also provide neuroanatomical links between PD-OH and cognitive impairment, for which the latter has been associated with altered central noradrenergic function (21, 22). A strong candidate link here could be the locus coeruleus (LC) (23), which is pathologically affected in PD early, progressively, and to greater degree than the substantia nigra pars compacta (SNc) (24, 25). The LC is the primary source of central noradrenergic signaling, with extensive cortical, subcortical, and spinal efferent projections; its functional roles are thus many, but importantly include autonomic regulation, arousal/attention, and learning/memory (26, 27). The LC exerts a net sympathoexcitatory effect on cardiovascular function, with positive chronotropic and vasopressor effects through its interaction with the baroreflex arc, including through direct inhibition of brainstem cardio-parasympathetic nuclei (26, 28). The LC’s potential role for cognition likely involves modulation of cerebral blood flow (29) and attention/cognitive control (30, 31), and moderating medial temporal synaptic plasticity (32, 33).

Few studies have directly tested for relationships between LC structure/function, OH, and cognitive symptoms in PD. Those that have done so have primarily utilized PET imaging and neuromelanin sensitive (NM-)MRI. One study, by Sommerauer and colleagues(21), found that reduced norepinephrine transporter availability (11C-MeNER PET) correlated with orthostatic vitals sign (OVS) changes in PD, but NM-MRI structural measures did not correlate with OVS; these findings suggest at least LC dysfunction is involved in PD-OH. Similarly, a brief pathological report found no LC structural relationship with OH presence (34). However, the NM-MRI study’s negative result may have related to methodological issues, statistical power, and lack of a direct comparison between PD with/without OH. Additionally, in the pathological study, patients had advanced disease duration and OH-presence was based on chart diagnosis alone, which likely affected results. Cognitive changes associated with normal aging, Alzheimer’s disease, and PD have also been linked to LC integrity (35–38), and two recent NM-MRI studies linked disrupted LC integrity in PD, compared to healthy controls, to worse cognitive performance (36, 38). Taken together there is a strong premise for involvement of the LC in PD-OH and cognitive decline and for use of NM-MRI to examine its role. Findings supporting this interrelationship could have practice changing implications for treatments targeting the LC-norepinephrine system.

Guided by the hypothesis that LC pathology contributes to OH in PD, and potentially to cognitive decline as well, we compared NM-MRI derived LC volumes in early-moderate PD patients with/without OH. We then looked for correlational relationships across subjects between LC volume and OVS. As a preliminary
assessment of the LC's role in cognition, we additionally correlated LC volumes with scores of the Montreal Cognitive Assessment (MoCA). We predicted a reduction in LC volumes in PD-OH, compared to PD with no OH. A secondary prediction was that LC volume would positively correlate with cognitive scores. Finally, recent work has found that PD-related OH, independent of OHSx, confers risk of cognitive decline (39). Some have proposed that OHSx may rely on function of adrenergic output by the LC (40). If true, this observation would indicate biomarker-based approaches may enhance general studies of PD-related OH. We thus also tested for relationships between OHSx, OVS, and LC volume; this analysis also included scales for depression, anxiety, and fatigue, as atypical OHSx may overlap with these non-motor symptoms. We predicted that LC volume may be associated with OHSx, but that OVS would be more so; additionally, we predicted significant associations between OHSx and those of depression, anxiety, and fatigue.

**Methods**

**Participants and clinical evaluation:**

This prospective study was approved by the Emory institutional review board. Data were collected between 2012 and 2017. All participants provided written informed consent. In this study, 62 PD participants were recruited from the Emory University Movement Disorders Clinic. All PD participants were diagnosed by a fellowship-trained movement disorders neurologist according to the United Kingdom Parkinson's Disease Society Brain Bank criteria (41). Study exclusion criteria were: (1) drug-induced or atypical parkinsonisms; (2) a history of multiple sclerosis, territorial ischemic stroke, hemorrhagic stroke, epilepsy, parenchymal brain tumor, moderate-to-severe head trauma, hydrocephalus, other neurodegenerative diseases; or (3) treatment with dopamine blocking drugs.

Demographic information including sex, age, and education was collected for each participant. Disease motor severity was evaluated using the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III). Dopaminergic medication strength and daily doses were recorded to calculate levodopa equivalent daily doses (LEDDs) using the Parkinson’s measurement toolbox (https://www.parkinsonsmeasurement.org/toolBox/levodopaEquivalentDose.htm). Cognition was assessed using the Montreal Cognitive Assessment (MoCA) (43). The Non-motor Symptoms Questionnaire (NMSQ) (44) assessed general non-motor symptoms, including OHSx (question #20). Depressive and anxiety symptoms were assessed with the Beck Depression Inventory II (BDI) (45) and Beck Anxiety Inventory (BAI) (46), respectively. Symptoms of fatigue were assessed with the Fatigue Questionnaire (FatQ) (47, 48). Both motor symptoms and OVS were tested during the 'ON' medication state. OVS (systolic and diastolic blood pressure, SBP/DBP, and heart rate, HR) were measured after resting supine for several minutes and then repeated after one minute of active standing. Presence of OH was determined based on standard clinical criteria of either a drop in SBP of 20 or more mmHg or drop in DBP of 10 or more mmHg (49). Supine hypertension was determined based on supine SBP of 140 mmHg or higher or DBP of 90 mmHg or higher (14).
MRI scanning and Image analysis:

MRI data for 22 PD patients were acquired with a Siemens Trio 3 Tesla scanner (Siemens Medical Solutions, Malvern, PA, USA) at Emory University with a 12-channel receive-only head coil. NM-MRI data was acquired using a magnetization transfer (MT)-prepared 2D gradient echo (GRE) sequence with parameters: echo time (TE)/repetition time (TR)=2.68ms/337ms, flip angle (FA)=40°, slice thickness=3mm, in plane resolution 0.39x0.39mm², field of view (FOV)=162x200mm², 15 contiguous slices, 7 measurements, 470 Hz/pixel bandwidth, MT-preparation pulse (FA=300°, 1.2kHz off resonance, 10ms duration), and scan time 16 minutes 17 seconds. A T₁-weighted magnetization-prepared rapid gradient echo (MP-RAGE) sequence (parameters: TE/TR=3.02ms/2600ms, inversion time=800ms, FA=8°, voxel size=1.0x1.0x1.0mm³) was used for common space registration.

The Trio scanner was upgraded to a Prisma-Fit scanner using the same transmitter, and MRI data of 40 more PD patients were acquired with this upgraded scanner at Emory University using a 64-channel receive-only coil. NM-MRI data were acquired using a MT-prepared 2D GRE sequence with the following parameters: TE/TR=3.10ms/354ms, 416x512 imaging matrix, 162x200mm (0.39x0.39x3mm³), 15 contiguous slices, 7 measurements, flip angle=40°, 470 Hz/pixel receiver bandwidth, and MTC pulses (300°, 1.2kHz off resonance, 10ms duration), scan time 17min-12s. A T₁-weighted magnetization-prepared MP-RAGE sequence (TE/TR=2.46ms/1900ms, inversion time=900ms, FA=9°, voxel size=0.8x0.8x0.8mm³) was used for common space registration.

On the sagittal T₁-weighted images for both cohorts, the GRE scan slices were positioned perpendicular to the dorsal edge of the brain stem at midline along the fourth ventricle, starting from the lower pons (below the most caudal extent of LC), covering the SNc and LC.

MRI data were processed using the FMRIB Software Library (FSL) and MATLAB. NM-MRI images were motion corrected by registering the seven GRE measurements to the first image using the FMRIB Linear Image Registration Tool (FLIRT) and then averaged. These images were then used for analysis. Next, individual subject space and common space transformations took place using a previously published method from our group.

SNc and LC volumes were segmented with a semi-automated thresholding method as previously described. A reference region of interest (ROI) in each cerebral peduncle was transformed from standard space to individual subject space using the previously described transformations. The mean and standard deviation (SD) of the signal intensities were determined for the reference ROIs. Voxels that were three SD or four SD greater in intensity than the mean intensity in the reference region were identified as SNc or LC, respectively. Thresholding was restricted to the anatomic location of SNc and LC using dilations of previously reported probabilistic standard space masks.

Statistical Analysis:
Subject demographics between OH/no-OH were compared using either independent samples T-testing (continuous variables) or Chi-square testing (categorical variables). MANCOVA testing was used to compare LC and SNC volume differences between OH/no-OH groups. Covariates of non-interest in this model included demographic/clinical variables found to be significantly different, or closely trending, between groups as well as variables considered strong conceptual confounders. Next, we evaluated relationships between LC volume, OVS, and MoCA using one-tailed partial correlations based on the hypothesis that increasing neurodegeneration (i.e., neuromelanin loss) is associated with more symptoms. Age was included as a covariate in OVS partial correlation analyses, given the association between greater age and risk of OH (58), as was scanner type. Next, we examined associations between OHSx and other variables. First, we compared relative percentages of OHSx between OH/no-OH groups using responses to #20 of the NMSQ (“Feeling light-headed, dizzy or weak standing from sitting or lying”) using Chi-square testing. We then compared demographic and clinical variables between OHSx groups. We determined a priori to assess relationships between OHSx, LC/SNC volumes, OVS, and certain non-motor scales (BDI, BAI, FatQ) in a MANOVA model. The selected non-motor scales were chosen because some questions on these scales overlap with atypical symptoms of OH (15). For each analysis the threshold for significance was p<0.05. Both uncorrected and false discovery rate (FDR) (59) corrected p-values are reported for correlational analyses.

Results

Subject clinicodemographic data, across and between OH groups, are found in Table 1. In general the OH/no-OH groups were well matched with respect to demographics; OH tended towards being slightly older, p=0.06. There was no significant group difference between scanner type utilized, disease duration, LEDDs, or number of anti-hypertensives used. The OH group tended to have slightly higher motor scores (p=0.06). No group differences were found for non-motor scale scores. OVS differed between groups for SBP (supine and standing, individually), standing DBP, and supine HR. The OH group tended toward a greater percentage of supine hypertension (p=0.08).

One-tailed partial correlation results (age, scanner type covariates) between LC volume, OVS, and MoCA are visualized as scatter plots in Figure 2. In general, lower LC volumes correlated with greater orthostatic drop in SBP (Fig. 2A; r=0.24, p_{unc}=0.033, p_{FDR}=0.043) and DBP (Fig. 2B; r=0.25, p_{unc}=0.027, p_{FDR}=0.043). On the other hand, lower LC volumes correlated with greater degree of orthostatic HR increase (Fig. 2C; r=-0.32, p_{unc}=0.006, p_{FDR}=0.024). LC volume correlated positively MoCA score (r=0.22, p_{unc}=0.043, p_{FDR}=0.046).

Subject demographics comparing OHSx groups (answering ‘yes/no’ on question 20 of the NMSQ) are found in Supplementary Table 1. These baseline characteristics were compared between these groups for consideration of inclusion into a MANOVA that would further examine characteristics of those with OHSx. No significant differences in demographics, scanner type, or clinical variables were found, with exception of BDI and FatQ results (greater in those with OSHx, independent T-test p=0.016 and 0.029, respectively), with standing DBP trending (p=0.08). OH-patients were more likely to endorse OHSx (Chi Sq. p=0.047).
Relative percentages of OHSx stratified by OH-groups, and factors underlying report of OHSx, are found in Fig. 3. Among OH, 66% reported OHSx, with the remainder denying symptoms. Conversely, 34% of no-OH endorsed OHSx. This reciprocal relationship is shown in Fig. 3A. MANOVA testing across all PD patients (N=62) found no relationship between OHSx and LC/SNc volumes (Fig. 3B). Regarding OVS changes and OHSx: orthostatic SBP change trended toward significance (F=3.8, p=0.055); DBP change was significantly associated with OHSx (F=4.3, p=0.043); HR change was not associated with OHSx. BAI scores were not associated with OHSx, but both BDI (F=6.6, p=0.012) and FatQ (F=5.13, p=0.027) were associated with OHSx.

**Discussion**

The mechanism underlying central contribution to OH in PD is unresolved. We hypothesized that LC is a strong candidate for a central substrate (23). To test this hypothesis, we derived LC volumes using NM-MRI and compared them between PD patients with and without OH; we subsequently assessed correlations between LC volume and OVS; correlations between LC volumes and cognitive testing (MoCA) was also explored to examine potential influence on cognition. Prior studies report cognitive decline occurs in PD-OH to greater degree than in those without OH, irrespective of OHSx (12,13,39); additionally a role for LC function has been proposed for occurrence of OHSx (40). We thus examined the relationship of OHSx with LC/SNc volume and OVS, with symptoms of depression, anxiety, and fatigue also included given similarity between these and atypical OHSx.

Our primary prediction, that LC volume would be reduced in the OH group, compared to the no-OH group, was confirmed; SNc volumes did not differ between groups. In line with our primary prediction, LC volumes were additionally correlated with OVS across subjects. We found a weaker correlation between LC volume and cognition. These findings provide further evidence that LC neurodegeneration is a substrate for autonomic dysfunction in PD. However, the weak LC-MoCA correlation suggests a need for more extensive testing in a larger cohort. Our main secondary prediction related to OHSx; namely that LC volume and OVS would be predictive of OHSx. This prediction was partly confirmed; while no relationship between structural measures (LC/SNc volume) and OHSx was found, OVS (namely DBP change, to a lesser extent SBP) were predictive of OHSx. However, compared to OVS, OHSx was better predicted by depressive and fatigue symptoms.

Neuropathologically, LC is affected very early in PD and to a greater extent than SNc (24,25), compromising the brain and spinal cord's primary source of noradrenergic innervation. The LC has several ascending and descending outputs that generally inhibit central preganglionic parasympathetic nuclei and activate preganglionic sympathetic pathways to result in a net sympathetic increase: projections to the hypothalamic paraventricular nucleus promote behavioral arousal and suppression of the baroreflex; descending alpha2-receptor activation in the vagal dorsal motor nucleus and nucleus ambiguus reduces parasympathetic cardiovascular effects; LC also provides alpha1-mediated excitatory influence to spinal preganglionic sympathetic interomediolateral nuclei (60). One exception to the LC's general role in increasing in sympathetic activation is its inhibitory (alpha2) effects on rostroventrolateral...
medulla (RVLM) (60), which is the main sympathetic nucleus in the baroreflex arc (61). Nevertheless, it is logical that LC pathology, by impairing its overall sympathetic cardiovascular effects, contributes to cardiovascular dysautonomia in PD.

Our findings complement recent neuroimaging studies suggesting central contributions to dysautonomia in PD via structural (20) and functional alterations of central autonomic regulators (19,21). Indeed, a prior study by Sommerauer and colleagues found reduced cerebral norepinephrine transporter availability (via $^{11}$C-MeNER PET) correlated with OVS changes in PD (21). Our results add to these findings, supporting the hypothesis that structural disruption of LC contributes to PD-OH; not only were LC volumes lower in OH patients, LC volumes also generally correlated with OVS across all PD subjects. Furthermore, our findings were specific to LC, as no such reduction was observed in the SNc for the OH group. One curious result was a negative correlation between LC volume and HR changes across all PD subjects; i.e, lower LC volume was associated with greater orthostatic HR increase, which could be inconsistent with role in neurogenic OH (6). However, this effect may relate to a ‘release’ of LC’s typical inhibitory effects on RVLM (60), which could then contribute to an orthostatic HR increase. Interestingly, OH groups differed with respect to supine HR (lower in the OH group) but not standing HR. It is thus possible that LC pathology in PD may primarily affect orthostatic pressor response, with the blunted orthostatic HR change typical of neurogenic OH perhaps resulting from an alternative autonomic lesion, such as post-ganglionic cardiac sympathetic denervation (62).

Of note, our findings do contrast somewhat with structural findings by Sommerauer and colleagues (21), whose NM-MRI LC measures did not correlate with OVS. These differences likely relate to study methodology. The prior NM-MRI study did not directly compare OH vs. no-OH, utilizing only correlational analyses. Their protocol also restricted analysis to the 10 highest intensity voxels after manual region of interest (ROI) placement; this approach is subject to impacts from noise and operator-dependent variability. In contrast, we utilized semi-automated ROI placement and volume measurement using methods with high scan-rescan reproducibility (63,64). Similarly, a brief pathological report found no relationship between LC pathology and charted presence vs. absence of OH (34), However, this study utilized a cohort with advanced disease duration (averaging more than a decade), and OH designation was based on chart diagnosis alone; both of these factors likely affected results.

The LC has a well-established role with respect to attention and learning/memory via modulation of cerebral blood flow, frontal attentional/cognitive control mechanisms, and effects on memory and related synaptic plasticity (29,30,33,57,65,66). Prior work examining LC-related effects on PD cognitive impairment is limited, but supportive of LC playing a role: LC-related neuronal loss occurs earlier and to a greater degree than Meyert’s nucleus in PD (25); pharmacologic increase in NE levels improve cognitive performance in PD (67); NM-MRI based LC structural integrity correlated with cognition in PD (38) and is lower in PD patients with mild cognitive impairment (MCI), in comparison to those without MCI and healthy controls (36). The correlation we observed between MoCA score and LC volume is consistent with these findings, but will require replication with more extensive cognitive testing and a larger cohort of patients with OH.
Establishing a role for the LC in the pathophysiology of OH, and potentially cognitive impairment, in PD has implications for treatment, as centrally acting, noradrenergic medications may benefit patients from both perspectives. Atomoxetine, a norepinephrine transport inhibitor, is one example of a centrally and peripherally acting noradrenergic agent that has been examined in PD for effects on OH and cognition, though separately; multiple studies have found atomoxetine safe and effective for OH treatment, with better performance than the peripherally acting standard of care, alpha₁ agonist midodrine (68,69).

Additionally, atomoxetine's effects are greater in patients with central, rather than peripherally-based, autonomic failure (70). Atomoxetine has been experimentally used to improve measures of somnolence, impulsivity and frontal function, and global cognition in PD (67,71,72), and the response in this regard varies as a function of LC integrity (73). These cognitive effects have been posited to relate to greater noradrenergically mediated prefrontal top-down control and more effective coherence of cortico-coeruleal circuits particularly involving the subthalamic nucleus (74). Based on these observations in treatment trials of atomoxetine, our findings would suggest the need for further investigation of this or similar drugs as candidate treatments for OH and cognitive impairment in PD.

Accurate definition of OH is essential to establish mechanistic understanding of OH in PD. However, for unclear reasons, relatively few patients (~33%) with OH endorse typical OHSx (4,5). Interestingly, we observed a reciprocal pattern of typical OHSx in those with and without OH (Fig. 3A). The significant proportion of PD patients without OH that report putative OHSx, and vice versa, is clinically important; this is particularly the case given we found no relationship between LC volumes and OHSx (Fig. 3B), contrasting prior postulation on a role for the LC in this regard (40). Additionally, while OVS did significantly predict OHSx they did so less robustly than depressive and fatigue-related symptoms (Fig. 3B), which were not different in occurrence between OH groups (Table 1). Interpretation of these findings is challenging given a lack of mechanistic understanding of hypotension perception. However, results may relate to the frequent non-specificity of atypical OHSx, which can include several fatigue or depression scale symptoms (15). Our results may reflect some of this overlap, particularly given a significant number of no-OH patients endorsing OHSx. Our findings are additionally similar to those seen in orthostatic intolerance patients, in which OHSx correlates highly with those of depression and fatigue (75,76). It is possible that a more specific/in-depth questionnaire for OHSx would have led to findings more specific to OVS.

There are limitations to this study. First, though we have similar numbers of OH patients compared to prior work involving NM-MRI, our findings would be strengthened by greater numbers of OH patients. Future work would benefit from comparison of LC volumes in the PD population with those of healthy controls as well. Similarly, our cognition-related results may have been more robust with a wider range of cognitive performance or more in-depth testing. Patient OVS may have been influenced by measurement during the ON-medication state; comparison of OFF and ON-state measures would potentially provide assurance of PD-mediated OH. It is notable, though, that our OH group generally had lower LEDDs. We performed no formal autonomic testing to confirm neurogenic OH, using instead clinically relevant bedside measures. Nevertheless, it is notable that our OH group’s average orthostatic HR change, divided
by SBP change (12bpm, 30mmHg), meets neurogenic OH criteria determined by Norcliffe-Kaufman and colleagues (77). We additionally included anti-hypertensive use in our models comparing groups. Measuring OVS by only one minute could have affected findings; however, one-minute measures are clinically relevant to OHSx and adverse OH events (78).

Conclusions

Using NM-MRI we found that LC volumes were lower in PD patients with OH, compared to no-OH, and that LC volumes correlated with OVS across subjects; a preliminary weaker correlation between LC volume and cognition was also found. In contrast, LC volumes were not associated with OHSx; instead, OHSx was related to OVS and, to a greater extent, depressive and fatigue-related symptoms. Future work will need to validate these findings in a larger cohort of PD patients with OH, during OFF-medication state, with a wider range of cognitive ability and testing, and for a greater duration of orthostatic challenge. Nevertheless, these findings support the notion that central autonomic dysfunction plays a role in PD-related dysautonomia and suggest that LC may serve as a common central substrate connecting OH and cognitive function in PD. Centrally acting noradrenergic treatments may thus benefit patients suffering from these non-motor symptoms. Our findings also support the need to undertake more in-depth clinical screening for OH, as symptoms may be infrequent and non-specific.

Abbreviations

OH=Orthostatic hypotension; PD=Parkinson disease; LC=Locus coeruleus; OHSx=Orthostatic hypotension symptoms; OVS=orthostatic vital signs; SNc=Substantia nigra pars compacts; FDR=False discovery rate; NM-MRI=Neuromelanin sensitive magnetic resonance imaging; LEDDs=Levodopa equivalent daily doses; MoCA=Montreal Cognitive Assessment; BDI=Beck Depression Inventory II; BAI=Beck Anxiety Inventory; FatQ=Fatigue Questionnaire; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; HR=Heart rate; FDR=False discovery rate; RVLM=Rostroventrolateral medulla

Declarations

Ethics approval and consent to participate:

This study received approval from the Emory University Institutional Review Board. All subjects provided informed consent prior to inclusion.

Consent for publication

All authors have read the manuscript as submitted for publication and have provided consent for publishing.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Competing interests**

Dr. Paul A. Beach: None

Dr. Nithin Kurra: None

Dr. Kristy Hwang: None

Dr. Xiaoping Hu: None

Dr. Jason Langley: None

Dr. Daniel E Huddleston: inventor on an issued patent (U.S. patent #9600881, 3/21/17) which covers aspects of the NM-MRI methods discussed here.

**Funding**

Dr. Huddleston is supported by The Michael J. Fox Foundation grants MJFF-10854 and MJFF-010556, NIH-NINDS 1K23NS105944-01A1, the American Parkinson’s Disease Association Center for Advanced Research (Emory University), and the Lewy Body Dementia Association Research Center of Excellence (Emory University)

**Authors’ contributions**

Dr. Paul A. Beach: All rounds of manuscript drafting, statistical analysis design and execution, conception of the project.

Dr. Nithin Kurra: Data collection and collation, review of manuscript.

Dr. Kristy Hwang: Review and critique of the manuscript.

Dr. Xiaoping Hu: Organization and execution of research project, review and critique of manuscript.

Dr. Jason Langley: Organization and execution of research project, review and critique of manuscript, data analysis and image processing.

Dr. Daniel E Huddleston: Conception of research project, study organization and data collection management, review and critique of statistical analysis, review and critique of manuscript.

**Acknowledgements**

The authors would like to thank all patients who participated in this study.
1. Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini S, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol. 2003 Oct;60(10):1400–4.

2. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarrello TP, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2009 Aug 15;24(11):1641–9.

3. Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Myllylä VV. Orthostatic hypotension, balance and falls in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2009 Apr 15;24(5):745–51.

4. Palma J-A, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord Off J Mov Disord Soc. 2015 Apr 15;30(5):639–45.

5. Freeman Roy, Illigens Ben M.W., Lapusca Razvan, Campagnolo Marta, Abuzinadah Ahmad R., Bonyhay Istvan, et al. Symptom Recognition Is Impaired in Patients With Orthostatic Hypotension. Hypertension [Internet]. 2020 May 1 [cited 2021 May 17];75(5):1325–32. Available from: http://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.119.13619

6. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008 Feb 7;358(6):615–24.

7. Joseph A, Wanono R, Flamant M, Vidal-Petiot E. Orthostatic hypotension: A review. Nephrol Ther. 2017 Apr;13 Suppl 1:S55–67.

8. Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest Study. Neurology [Internet]. 2009 Mar 31 [cited 2021 Jun 4];72(13):1121–6. Available from: https://n.neurology.org/content/72/13/1121

9. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord Off J Mov Disord Soc. 2008 Apr 30;23(6):837–44.

10. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol [Internet]. 2012 Aug 1 [cited 2021 Jun 4];11(8):697–707. Available from: https://www.sciencedirect.com/science/article/pii/S1474442212701527

11. Centi J, Freeman R, Gibbons CH, Neargarder S, Canova AO, Cronin-Golomb A. Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology. 2017 Jan 3;88(1):17–24.

12. Kim J-S, Oh Y-S, Lee K-S, Kim Y-I, Yang D-W, Goldstein DS. Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology [Internet]. 2012 Sep 25 [cited 2021 May 10];79(13):1323–31. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448741/
13. Udow SJ, Robertson AD, Maclntosh BJ, Espay AJ, Rowe JB, Lang AE, et al. “Under pressure”: is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies? J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1311–21.

14. Longardner K, Bayram E, Litvan I. Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease. Front Neurol. 2020;11:897.

15. Kaufmann H, Palma J-A. Neurogenic orthostatic hypotension: the very basics. Clin Auton Res [Internet]. 2017 [cited 2019 Mar 5];27(Suppl 1):39–43. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524853/

16. Palma J-A, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord Off J Mov Disord Soc. 2018 Mar;33(3):372–90.

17. Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson disease. Handb Clin Neurol. 2013;117:259–78.

18. Nakamura T, Hirayama M, Hara T, Mizutani Y, Suzuki J, Watanabe H, et al. Role of cardiac sympathetic nerves in preventing orthostatic hypotension in Parkinson's disease. Parkinsonism Relat Disord. 2014 Apr;20(4):409–14.

19. Dayan E, Sklerov M, Browner N. Disrupted hypothalamic functional connectivity in patients with PD and autonomic dysfunction. Neurology. 2018 Jun 5;90(23):e2051–8.

20. Pyatigorskaya N, Mongin M, Valabregue R, Yahia-Cherif L, Ewenczyk C, Poupon C, et al. Medulla oblongata damage and cardiac autonomic dysfunction in Parkinson disease. Neurology. 2016 Dec 13;87(24):2540–5.

21. Sommerauer M, Fedorova TD, Hansen AK, Knudsen K, Otto M, Jeppesen J, et al. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. Brain [Internet]. 2018 Feb 1 [cited 2018 Apr 17];141(2):496–504. Available from: https://academic-oup-com.proxy.library.emory.edu/brain/article/141/2/496/4759463

22. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2014 Apr 15;29(5):634–50.

23. McDonald C, Newton JL, Burn DJ. Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association? Mov Disord Off J Mov Disord Soc. 2016 Jul;31(7):937–46.

24. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging [Internet]. 2003 Mar 1;24(2):197–211. Available from: http://www.sciencedirect.com/science/article/pii/S0197458002000659

25. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003 Mar;60(3):337–41.

26. Szabadi E. Functional neuroanatomy of the central noradrenergic system. J Psychopharmacol Oxf Engl. 2013 Aug;27(8):659–93.

27. Benaroch EE. Locus coerules. Cell Tissue Res. 2018 Jul;373(1):221–32.
28. Wang X, Piñol RA, Byrne P, Mendelowitz D. Optogenetic Stimulation of Locus Ceruleus Neurons Augments Inhibitory Transmission to Parasympathetic Cardiac Vagal Neurons via Activation of Brainstem α1 and β1 Receptors. J Neurosci [Internet]. 2014 Apr 30 [cited 2021 May 10];34(18):6182–9. Available from: https://www.jneurosci.org/content/34/18/6182

29. Bekar LK, Wei HS, Nedergaard M. The locus coeruleus-norepinephrine network optimizes coupling of cerebral blood volume with oxygen demand. J Cereb Blood Flow Metab [Internet]. 2012 Dec [cited 2021 May 14];32(12):2135–45. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519408/

30. Bari A, Xu S, Pignatelli M, Takeuchi D, Feng J, Li Y, et al. Differential attentional control mechanisms by two distinct noradrenergic coeruleo-frontal cortical pathways. Proc Natl Acad Sci [Internet]. 2020 Nov 17 [cited 2021 Jun 3];117(46):29080–9. Available from: https://www.pnas.org/content/117/46/29080

31. Grueschow M, Kleim B, Ruff CC. Role of the locus coeruleus arousal system in cognitive control. J Neuroendocrinol [Internet]. 2020 [cited 2021 Jun 3];32(12):e12890. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/jne.12890

32. Bari BA, Chokshi V, Schmidt K. Locus coeruleus-norepinephrine: basic functions and insights into Parkinson's disease. Neural Regen Res. 2020 Jun;15(6):1006–13.

33. Poe GR, Foote S, Eschenko O, Johansen JP, Bouret S, Aston-Jones G, et al. Locus coeruleus: a new look at the blue spot. Nat Rev Neurosci. 2020 Nov;21(11):644–59.

34. Tong Q, Chen L. Lack of Association of Locus Coeruleus Pathology with Orthostatic Hypotension in Parkinson's Disease. J Park Dis. 2021;11(1):233–7.

35. Del Tredici K, Braak H. Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol [Internet]. 2016 Feb 1;42(1):33–50. Available from: http://onlinelibrary.wiley.com/doi/abs/10.1111/nan.12298/abstract

36. Li Y, Wang C, Wang J, Zhou Y, Ye F, Zhang Y, et al. Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus. Mov Disord Off J Mov Disord Soc. 2019 Jun;34(6):884–92.

37. Takahashi J, Shibata T, Sasaki M, Kudo M, Yanezawa H, Obara S, et al. Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer’s disease: high-resolution fast spin-echo T1-weighted imaging. Geriatr Gerontol Int. 2015 Mar;15(3):334–40.

38. Prasuhn J, Prasuhn M, Fellbrich A, Strautz R, Lemmer F, Dreischmeier S, et al. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease. Neurology [Internet]. 2021 Jun 29 [cited 2021 Jul 8]; Available from: https://n.neurology.org/content/early/2021/06/29/WNL.000000000012444

39. Longardner K, Bayram E, Litvan I. Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease. Front Neurol [Internet]. 2020 [cited 2020 Oct 19];11. Available from: https://www.frontiersin.org/articles/10.3389/fneur.2020.00897/full?report=reader
40. Tipton PW, Cheshire WP. Mechanisms underlying unawareness of neurogenic orthostatic hypotension. Clin Auton Res Off J Clin Auton Res Soc. 2020 Jun;30(3):279–81.

41. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–4.

42. Fahn S, Elton R, Members of the UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale, Recent developments in Parkinson’s disease. 2nd ed. Florham Park, NJ: Macmillan Health Care Information; 1987. 153–63, 293–304 p.

43. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695–9.

44. Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord Off J Mov Disord Soc. 2006 Jul;21(7):916–23.

45. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. An Inventory for Measuring Depression. Arch Gen Psychiatry. 1961;4(6):561–71.

46. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988 Dec;56(6):893–7.

47. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res. 1993 Oct;37(7):753–62.

48. Herlofson K, Larsen JP. Measuring fatigue in patients with Parkinson’s disease - the Fatigue Severity Scale. Eur J Neurol. 2002 Nov;9(6):595–600.

49. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996 May;46(5):1470.

50. Langley J, Huddleston DE, Crosson B, Song DD, Factor SA, Hu X. Multimodal assessment of nigrosomal degeneration in Parkinson’s disease. Parkinsonism Relat Disord. 2020 Nov;80:102–7.

51. Chen X, Huddleston DE, Langley J, Ahn S, Barnum CJ, Factor SA, et al. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. Magn Reson Imaging. 2014 Dec;32(10):1301–6.

52. Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2011 Aug 1;26(9):1633–8.

53. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23:S208–19.
54. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001 Jun;5(2):143–56.

55. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage. 2002 Oct;17(2):825–41.

56. Langley J, Huddleston DE, Liu CJ, Hu X. Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI. Magma N Y N. 2017 Apr;30(2):121–5.

57. Langley J, Hussain S, Flores JJ, Bennett IJ, Hu X. Characterization of age-related microstructural changes in locus coeruleus and substantia nigra pars compacta. Neurobiol Aging [Internet]. 2020 Mar 1 [cited 2021 Jun 30];87:89–97. Available from: https://www.sciencedirect.com/science/article/pii/S0197458019304245

58. Cheng S, Xanthakis V, Sullivan LM, Vasan RS. Blood pressure tracking over the adult life course: patterns and correlates in the Framingham heart study. Hypertens Dallas Tex 1979. 2012 Dec;60(6):1393–9.

59. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol [Internet]. 1995 [cited 2021 Jun 30];57(1):289–300. Available from: https://www.jstor.org/stable/2346101

60. Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation. Curr Neuropharmacol. 2008 Sep;6(3):235–53.

61. Benarroch EE. The arterial baroreflex: Functional organization and involvement in neurologic disease. Neurology [Internet]. 2008 Nov 18 [cited 2021 Jul 8];71(21):1733–8. Available from: https://n.neurology.org/content/71/21/1733

62. Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis. Neurobiol Dis [Internet]. 2012 Jun [cited 2021 Mar 16];46(3):572–80. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0969996111003573

63. van der Pluijm M, Cassidy C, Zandstra M, Wallert E, de Bruin K, Booij J, et al. Reliability and Reproducibility of Neuromelanin-Sensitive Imaging of the Substantia Nigra: A Comparison of Three Different Sequences. J Magn Reson Imaging JMRI. 2021 Mar;53(3):712–21.

64. Langley J, Huddleston DE, Liu CJ, Hu X. Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI. Magn Reson Mater Phys Biol Med [Internet]. 2017 Apr 1 [cited 2021 Mar 2];30(2):121–5. Available from: https://doi.org/10.1007/s10334-016-0590-z

65. Langley J, Hussain S, Huddleston DE, Bennett IJ, Hu XP. Impact of locus coeruleus and its projections on memory and aging. ArXiv210212522 Phys [Internet]. 2021 Feb 26 [cited 2021 Jun 30]; Available from: http://arxiv.org/abs/2102.12522

66. Wilson RS, Nag S, Boyle PA, Hizel LP, Yu L, Buchman AS, et al. Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology. 2013 Mar 26;80(13):1202–8.

67. Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, et al. Targeting impulsivity in Parkinson's disease using atomoxetine. Brain J Neurol. 2014 Jul;137(Pt 7):1986–97.
68. Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, et al. Efficacy of Atomoxetine Versus Midodrine for the Treatment of Orthostatic Hypotension in Autonomic Failure. Hypertension [Internet]. 2014 Dec 1 [cited 2021 Jun 9];64(6):1235–40. Available from: https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.114.04225

69. Byun J, Kim D, Moon J, Shin H-R, Sunwoo J, Lee W, et al. Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension. Ann Clin Transl Neurol [Internet]. 2019 Dec 19 [cited 2021 Jun 9];7(1):112–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952305/

70. Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, et al. Norepinephrine Transporter Blockade With Atomoxetine Induces Hypertension in Patients With Impaired Autonomic Function. Hypertension [Internet]. 2007 Jul 1 [cited 2021 Jun 9];50(1):47–53. Available from: http://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.107.089961

71. Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord Off J Mov Disord Soc. 2009 Jan 30;24(2):277–82.

72. Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010 Aug 3;75(5):448–55.

73. O'Callaghan C, Hezemans FH, Ye R, Rua C, Jones PS, Murley AG, et al. Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease. Brain [Internet]. 2021 Mar 30 [cited 2021 Jun 9];(awab142). Available from: https://doi.org/10.1093/brain/awab142

74. Bari A, Aston-Jones G. Atomoxetine modulates spontaneous and sensory-evoked discharge of locus coeruleus noradrenergic neurons. Neuropharmacology. 2013 Jan;64:53–64.

75. Moon J, Kim D-Y, Byun J-I, Sunwoo J-S, Lim J-A, Kim T-J, et al. Orthostatic intolerance symptoms are associated with depression and diminished quality of life in patients with postural tachycardia syndrome. Health Qual Life Outcomes [Internet]. 2016 Oct 12 [cited 2021 Jun 4];14. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059908/

76. Pandian JD, Dalton K, Henderson RD, McCombe PA. Postural orthostatic tachycardia syndrome: an underrecognized disorder. Intern Med J. 2007 Aug;37(8):529–35.

77. Norcliffe-Kaufmann Lucy, Kaufmann Horacio, Palma Jose-Alberto, Shibao Cyndya A., Biaggioni Italo, Peltier Amanda C., et al. Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Ann Neurol [Internet]. 2018 Feb 5 [cited 2018 Apr 17];83(3):522–31. Available from: https://onlinelibrary-wiley-com.proxy.library.emory.edu/doi/abs/10.1002/ana.25170

78. Juraschek SP, Daya N, Rawlings AM, Appel LJ, Miller ER, Windham BG, et al. Association of History of Dizziness and Long-term Adverse Outcomes With Early vs Later Orthostatic Hypotension Assessment Times in Middle-aged Adults. JAMA Intern Med. 2017 Sep 1;177(9):1316–23.

Tables
Table 1 - Subject demographics
|                               | All PD (N=62) | OH (N=9) | No-OH (N=53) | p (OH v no-OH) |
|-------------------------------|---------------|----------|--------------|----------------|
|                               | mean (SEM) or % |          |              |                |
| Age (years)                  | 62.2 (1.2)    | 67.4 (3.0) | 61.3 (8.9)   | 0.06           |
| Gender (% F)                 | 43.5          | 44.4     | 43.4         | 0.95           |
| Race (%)                     |               |          |              | 0.47           |
| Caucasian                    | 91.9          | 88.9     | 92.5         |                |
| African American             | 3.2           | 11.1     | 1.9          |                |
| Hispanic                     | 1.6           | 0        | 3.8          |                |
| other                        | 1.6           | 0        | 1.9          |                |
| Education (years) $\dagger$  | 16.6 (0.44)   | 15.4 (0.78) | 16.8 (0.49) | 0.29           |
| Scanner Type (% Trio | Prisma)      | 35.5 | 64.5 | 44.4 | 55.6 | 34 | 66 | 0.54 |
| Disease Duration (years) $^\wedge$ | 4.9 (0.52)    | 3.4 (1.1) | 5.2 (0.57) | 0.26           |
| LEDDs (mg)                   | 671.7 (53.8)  | 497.8 (106.1) | 701.3 (59.7) | 0.19           |
| UPDRS-III                    | 19.1 (1.0)    | 23.9 (2.7) | 18.28 (1.1) | 0.06           |
| Number anti-hypertensives    | 0.31 (0.082)  | 0.44 (0.34) | 0.28 (0.078) | 0.49           |
| MoCA                         | 27.6 (0.27)   | 27.8 (0.85) | 27.8 (0.28) | 0.15           |
| BDI                          | 6.7 (0.73)    | 7.1 (2.2)  | 6.7 (0.78)   | 0.85           |
| FatQ                         | 26.1 (1.5)    | 25.4 (3.6) | 26.3 (1.7)   | 0.85           |
| NMSQ total                   | 8.1 (0.62)    | 8.8 (2.0)  | 8.0 (0.65)   | 0.67           |
| BAI                          | 7.4 (0.88)    | 8.7 (2.8)  | 7.1 (0.92)   | 0.55           |
| Systolic BP supine (mmHg)    | 129.7 (2.0)   | 141.1 (5.7) | 127.8 (2.0) | 0.017*         |
| Systolic BP stand (mmHg)     | 121.11 (2.0)  | 109.9 (6.4) | 123.0 (2.0) | 0.019*         |
| Diastolic BP supine (mmHg)   | 77.2 (0.96)   | 80.2 (2.9)  | 76.7 (1.0)   | 0.2            |
| Diastolic BP stand (mmHg)    | 77.3 (1.3)    | 67.1 (4.8)  | 79.1 (1.1)   | 0.04*          |
| HR supine (BPM)              | 71.8 (1.6)    | 64.4 (2.3)  | 73.0 (1.7)   | 0.05*          |
| HR stand (BPM)               | 80.8 (1.4)    | 76.2 (2.7)  | 81.5 (1.6)   | 0.2            |
| Supine Hypertension Presence (%) | 30.6          | 55.6      | 26.4         | 0.08           |
Figures

Figure 1

Comparison of LC and SNc volumes (mm3) between PD with and without OH. A) Mean LC volume (+/- SEM; N) in PD without OH (no-OH) was 5.4 (+/- 0.44; 53) and, in PD with OH, LC volume was 2.7 (+/-0.63; 9). B) Mean SNc volume in the no-OH group was 350.3 (+/- 14.7; 53) and in the OH group SNc volume was 313.4 (+/- 35.9; 9). Box midline represents median volumes per group and whisker lines represent 10th to 90th percentiles. * Significant finding (p<0.05); ns = non-significant (p>0.05).
Figure 2

Partial correlations between LC volumes, OVS changes from lying to standing. Scatter plots represent one-tailed partial correlations (age & scanner type covariates) color stratified by presence or not of OH. OVS changes reflect standing - supine calculations (negative BP change = an orthostatic drop, positive HR change = orthostatic increase). r = partial correlation coefficients; punc = uncorrected p-values; pFDR = FDR corrected p-values. Solid line represents linear regression line across subjects with dotted lines representing 95% confidence intervals.

Figure 3

Characteristics of OH symptom presence across subjects. A) OH symptom presence was more likely in OH (66%) compared to no-OH (32%); B) Results of MANOVA findings for OH symptom presence across all PD subjects (N=62). Symptoms were more likely to occur based on greater orthostatic diastolic blood pressure drop (a trend was found for systolic blood pressure), greater degree of depressive symptoms (BDI), and greater degree of fatigue symptoms (FatQ). * Statistical threshold p<0.05 met for Chi-Square testing (left) and MANOVA results (right).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryMaterial.docx